Investigational drug · Phase 3
NVD003
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Congenital Pseudarthrosis of Tibia.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "NVD003"
First trial start
2025
Sep 2, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NVD003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Congenital Pseudarthrosis of Tibia
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "NVD003" as an intervention, largest first.
- A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Congenital Pseudarthrosis of the Tibia.Pivotal-lookingRecruiting
Novadip BiosciencesIndustry
NCT07112443 · 12 participants (planned) · Start Sep 2, 2025 · Primary completion Jun 2032
Drug: NVD003 · For: Congenital Pseudarthrosis of Tibia
Sites: Phoenix, Arizona; Loma Linda, California; Baltimore, Maryland · 7 sites in all
Novadip BiosciencesIndustry
NCT05693558 · 4 participants (planned) · Start Nov 24, 2022 · Primary completion Jan 2025
Drug: NVD-003, an autologous 3D scaffold free osteogenic graft · For: Congenital Pseudarthrosis of Tibia
Sites: Baltimore, Maryland; Brussels, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Development of the Extended Lane and Sandu Score to Assess Osseous Repair.
Carrino JA, Ibad HA, Boesen M, et al. · J Orthop Res 2026
- An Autologous Human Adipose Stem Cell-Derived 3D Osteogenic Implant for Bone Grafting: From Development to First-in-Human Experience.
Gerich T, Docquier PL, Carrino JA, et al. · J Clin Med 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.